Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.45 USD
Change Today -0.0101 / -2.17%
Volume 87.2K
APPY On Other Exchanges
Symbol
Exchange
APPY is not on other exchanges.
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

venaxis inc (APPY) Snapshot

Open
$0.46
Previous Close
$0.46
Day High
$0.46
Day Low
$0.44
52 Week High
04/1/14 - $2.83
52 Week Low
02/3/15 - $0.40
Market Cap
14.1M
Average Volume 10 Days
237.6K
EPS TTM
$-0.44
Shares Outstanding
31.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENAXIS INC (APPY)

Related News

No related news articles were found.

venaxis inc (APPY) Related Businessweek News

No Related Businessweek News Found

venaxis inc (APPY) Details

Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company’s research and development activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

20 Employees
Last Reported Date: 03/28/14
Founded in 2000

venaxis inc (APPY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $325.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $231.8K
Consultant
Total Annual Compensation: $236.9K
Compensation as of Fiscal Year 2013.

venaxis inc (APPY) Key Developments

Venaxis, Inc. Receives Non-Compliance Notice From NASDAQ

On March 13, 2015, Venaxis, Inc. received a letter from The NASDAQ Stock Market LLC advising that for the previous 30 consecutive business days, the bid price of the company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2). This notification has no effect on the listing of the common stock at this time. NASDAQ stated in its letter that in accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), the company will be provided 180 calendar days, or until September 9, 2015, to regain compliance with the minimum bid price requirement. The NASDAQ letter also states that if, at any time before September 9, 2015, the bid price of the common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the NASDAQ staff will provide the company with written notification that it has achieved compliance with the minimum bid price requirement. If the company fails to regain compliance with the Bid Price Rule before September 9, 2015 but meets all of the other applicable standards for initial listing on the Nasdaq Capital Market with the exception of the minimum bid price, then the company may be eligible to have an additional 180 calendar days, or until March 8, 2016, to regain compliance with the Bid Price Rule. If the company does not regain compliance with the minimum bid price requirement by September 9, 2015, or in the event it is eligible for an additional 180 calendar day period, by March 8, 2016, the NASDAQ staff will provide the company with written notification that the common stock will be delisted from the NASDAQ Capital Market. At that time, the company may appeal the delisting determination to a NASDAQ Listings Qualifications Panel pursuant to applicable NASDAQ rules.

Venaxis, Inc. Announces Resignation of Donald R. Hurd as Senior Vice President and Chief Commercial Officer with effective from February 22, 2015

on February 13, 2015, Donald R. Hurd resigned as Senior Vice President and Chief Commercial Officer of Venaxis, Inc. effective as of February 22, 2015. As a result of such resignation, Mr. Hurd's Employment Agreement, dated as of May 23, 2012, with the company was terminated.

Venaxis, Inc. - Special Call

To discuss business matters, including the recent FDA "Not Substantially Equivalent" response

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APPY:US $0.45 USD -0.0101

APPY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APPY.
View Industry Companies
 

Industry Analysis

APPY

Industry Average

Valuation APPY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 160.0x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENAXIS INC, please visit www.venaxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.